We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
0
0 active
Approvals
2
Total approvals
Agencies
1
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
FDA
Food and Drug Administration
• BrePco Biopharma and Piramal Critical Care have received MHRA approval for Neoatricon, the first pediatric-specific dopamine hydrochloride formulation for treating hypotension in neonates, infants, and children. • Neoatricon addresses a critical gap in pediatric care by providing age-appropriate, ready-to-use solutions in two concentrations (1.5mg/mL and 4.5mg/mL), eliminating the risks associated with modifying adult formulations. • Piramal Critical Care has secured commercialization rights for the EU, UK, and Norway, marking the company's expansion into a new therapeutic area with potential to significantly improve outcomes for vulnerable pediatric patients.
